This study demonstrated that anti-PD-L1 therapy was superior in comparison with platinum-based chemotherapy in selected cases and led to FDA approval for first-line treatment with the drug in patients with advanced NSCLC (18). This evidence concerns the gene CD274 and non-small cell lung carcinoma.